Skip to content

EMST and TMS for Treatment of Dysphagia in Parkinson's Disease

Expiratory Muscle Strength Training (EMST) and Transcranial Magnetic Stimulation (TMS) for Treatment of Swallowing Disorders in Parkinson's Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02461082
Enrollment
53
Registered
2015-06-03
Start date
2015-05-31
Completion date
2018-08-28
Last updated
2018-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Brief summary

The purpose of the study is to examine the effectiveness of different methods for the treatment of dysphagia in Parkinson's disease (PD). More than 80% of patients suffering from PD develop dysphagia during the course of their disease leading to malnutrition, loss of life quality, weight loss and pneumonia, which is the leading cause of death in these patients. So far, only a few specific treatment approaches have been investigated in PD patients with swallowing disorders. The investigator want to compare a 4-week expiratory muscle strength training (EMST), transcranial magnetic stimulation (TMS), and combination of both with a sham therapy. Dysphagia severity before and after intervention is measured by flexible endoscopic evaluation of swallowing (FEES). For the evaluation of changes in cortical swallowing processing the investigators apply magnetoencephalography (MEG).

Interventions

The EMST is performed 4 weeks, 5 days per week, for 20 minutes per day, using a calibrated or sham, handheld device (EMST 150, Aspire Products, Gainesville, FL).

OTHERTranscranial magnetic stimulation (TMS)

A sham or active transcranial magnetic stimulation is performed at the last 5 days of EMST training.

Sponsors

Deutsche Parkinson Vereinigung
CollaboratorOTHER
University Hospital Muenster
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Hoehn & Yahr stages II-IV * Parkinson-related dysphagia * Oral nutrition * Ambulant setting * No change of medication for at least 4 weeks before study inclusion

Exclusion criteria

* Other causes for dysphagia * Other neurological disease potentially causing dysphagia * Dementia (MMSE\<25; Montreal cognitive assessment (MoCA)\<26) * Severe depression (BDI\>19) * Percutaneous endoscopic gastrostomy (PEG)

Design outcomes

Primary

MeasureTime frame
Dysphagia severity as measured by FEESFour weeks

Secondary

MeasureTime frame
Cortical reorganization of swallowing process as detected by MEGFour weeks and three month
Changes in quality of life as measured by the swallowing quality of life questionnaire (Swal-Qol)Four weeks and three months
Dysphagia severity as measured by FEESThree month

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026